P53 Immunolabeling in EUS-FNA Biopsy can Predict Low Resection Rate and Early Recurrence in Resectable or Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of hepato-biliary-pancreatic sciences"
DOI: 10.1002/jhbp.1286
Abstract: PURPOSE KRAS, P16, TP53, and SMAD4/DPC4 mutations are common in pancreatic ductal adenocarcinoma (PDAC). The study aimed to evaluate the association between gene mutations in pretreatment Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) samples and clinical… read more here.
Keywords: eus fna; loss; abnormal p53; p53 ... See more keywords
Defining an abnormal p53 immunohistochemical stain in Barrett's oesophagus‐related dysplasia: a single‐positive crypt is a sensitive and specific marker of dysplasia
Sign Up to like & getrecommendations! Published in 2022 at "Histopathology"
DOI: 10.1111/his.14848
Abstract: p53 is an independent risk stratification marker in Barrett's oesophagus (BE), but no universally accepted definition exists for abnormal p53 staining. Herein, we assess p53 stains in two cohorts to: (1) define abnormal p53 staining… read more here.
Keywords: marker; related dysplasia; dysplasia; abnormal p53 ... See more keywords